Dr. Reddys Laboratories is currently trading at Rs. 4109.00, up by 102.35 points or 2.55% from its previous closing of Rs. 4006.65 on the BSE.
The scrip opened at Rs. 4054.00 and has touched a high and low of Rs. 4127.20 and Rs. 4026.00 respectively. So far 10998 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 4189.35 on 10-Jun-2020 and a 52 week low of Rs. 2352.00 on 14-Aug-2019.
Last one week high and low of the scrip stood at Rs. 4189.35 and Rs. 3938.90 respectively. The current market cap of the company is Rs. 66579.34 crore.
The promoters holding in the company stood at 26.75%, while Institutions and Non-Institutions held 44.50% and 14.65% respectively.
Dr. Reddy's Laboratories along with its subsidiaries have launched Colchicine Tablets USP, a therapeutic equivalent generic version of Colcrys (colchicine) Tablets, 0.6 mg, approved by the U.S. Food and Drug Administration (USFDA).
The Colcrys brand and generic market had U.S. sales of approximately $491 million MAT for the most recent twelve months ending in March 2020 according to IQVIA Health. The company's Colchicine is available in 0.6 mg tablets in bottle count sizes of 30s and 100s.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1520.55 |
Dr. Reddys Lab | 6217.15 |
Cipla | 1405.40 |
Zydus Lifesciences | 953.50 |
Lupin | 1589.10 |
View more.. |